Global Idiopathic Intracranial Hypertension Market Report and Forecast 2023-2031

Global Idiopathic Intracranial Hypertension Market Report and Forecast 2023-2031

Global Idiopathic Intracranial Hypertension Market Outlook

The global idiopathic Intracranial hypertension market is expected to grow significantly during the forecast period of 2023-2031. The increasing prevalence of ADHD worldwide, coupled with the growing demand for effective treatments, is driving the growth of the market. The global ADHD treatment market is likely to grow at a CAGR of 4.27% during the forecast period.

Idiopathic Intracranial hypertension Market: Introduction

The global idiopathic intracranial hypertension (IIH) treatment market report by Expert Market Research provides an in-depth analysis of the market and its segments. IIH, also known as pseudotumor cerebri, is a neurological disorder characterized by increased intracranial pressure in the absence of any underlying pathology. The lack of effective treatments for IIH has been a major challenge for healthcare providers and researchers worldwide. The report covers the market for IIH treatment and provides a detailed analysis of the market size, growth, and trends.

The IIH treatment market is expected to witness significant advancements in the coming years. The development of novel therapies, such as surgical interventions and drug therapies, and the increasing focus on personalized medicine are likely to drive the growth of the market. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for the market players.

Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of IIH, potentially improving patient outcomes and reducing healthcare costs. As a result, the global IIH treatment market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.

Idiopathic Intracranial Hypertension Epidemiology

Idiopathic Intracranial Hypertension (IIH) is a rare neurological condition characterized by increased intracranial pressure in the absence of any underlying pathology. The exact prevalence of IIH is unknown, but it is estimated to affect 1-2 per 100,000 people in the general population. However, the incidence of IIH is increasing, particularly in obese women of childbearing age.

IIH is more common in women, with a female-to-male ratio of 9:1. The peak incidence of IIH occurs between the ages of 20 and 50, but the condition can affect individuals of any age, including children. The exact cause of IIH is unknown, but several risk factors have been identified, including obesity, female gender, and certain medications.

Idiopathic Intracranial Hypertension Market Segmentations

The market can be categorised into diagnosis method, and treatment channels.

Market Breakup by Diagnostic Method

  • Carbonic Anhydrase Inhibitors
  • Acetazolamide
  • Methazolamide
  • Others
  • Loop Diuretics
  • Furosemide
  • Others
  • Corticosteroids
  • Anticonvulsant
  • Topiramate
  • Others
Market Breakup by Treatment Channels
  • Public
  • Private
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Idiopathic Intracranial hypertension Market Scenario

The market for idiopathic intracranial hypertension (IIH) treatment is expected to grow significantly in the coming years, driven by the increasing prevalence of the condition and the growing demand for effective treatments. The lack of effective therapies for IIH has been a major challenge for healthcare providers and researchers worldwide, creating a significant unmet need in the market.

North America is the largest market for IIH treatment, followed by Europe and the Asia Pacific. The high prevalence of IIH in North America, coupled with the availability of advanced healthcare infrastructure, is driving the growth of the market in the region. Europe is also a significant market for IIH treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about IIH and the rising healthcare expenditure in the region.

Key Players in the Global Idiopathic Intracranial Hypertension Market

The report gives an in-depth analysis of the key players involved in the idiopathic Intracranial hypertension market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Teva Pharmaceutical Industries Ltd
  • Mylan N.V.
  • Pfizer, Inc.
  • Upsher-Smith Laboratories, LLC
  • Merck & Co., Inc.
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • Cadila Healthcare Ltd.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Idiopathic Intracranial Hypertension Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Idiopathic Intracranial Hypertension Treatment Market
8.1 Global Idiopathic Intracranial Hypertension Treatment Market Overview
8.2 Global Idiopathic Intracranial Hypertension Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Idiopathic Intracranial Hypertension Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Idiopathic Intracranial Hypertension Treatment Market Forecast Value (2023-2031)
8.2.2 Global Idiopathic Intracranial Hypertension Treatment Market by Diagnosis Method
8.2.2.1 Market Overview
8.2.2.1.1 Carbonic Anhydrase Inhibitors
8.2.2.1.1.1 Acetazolamide
8.2.2.1.1.2 Methazolamide
8.2.2.1.1.3 Others
8.2.2.1.2 Loop Diuretics
8.2.2.1.2.1 Furosemide
8.2.2.1.2.2 Others
8.2.2.1.3 Corticosteroids
8.2.2.1.4 Anticonvulsant
8.2.2.1.4.1 Topiramate
8.2.2.1.5 Others
8.2.3 Global Idiopathic Intracranial Hypertension Treatment Market by Treatment Channel
8.2.3.1 Market Overview
8.2.3.1.1 Public
8.2.3.1.2 Private
8.2.4 Global Idiopathic Intracranial Hypertension Treatment Market by Region
8.2.4.1 Market Overview
8.2.4.1.1 North America
8.2.4.1.2 Europe
8.2.4.1.3 Asia Pacific
8.2.4.1.4 Latin America
8.2.4.1.5 Middle East and Africa
9 North America Idiopathic Intracranial Hypertension Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Idiopathic Intracranial Hypertension Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Idiopathic Intracranial Hypertension Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Idiopathic Intracranial Hypertension Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Idiopathic Intracranial Hypertension Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Idiopathic Intracranial Hypertension Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Teva Pharmaceutical Industries Ltd
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Mylan N.V.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Pfizer, Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Upsher-Smith Laboratories, LLC
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Merck & Co., Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Astellas Pharma Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 AbbVie Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Cadila Healthcare Ltd.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Sanofi
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Sun Pharmaceutical Industries Ltd.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Global Idiopathic Intracranial Hypertension Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings